

## Osteoporosis Management in Women Who Had a Fracture (OMW) Measure

### Measure Description

The percentage of women 67–85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

- The measure is a weight of **(0.5)** star and is part of the **STARs P4P Incentive Program**.
- Members are included in the measure if they've suffered a fracture during the 12-month window that begins on July 1st of the year prior to the measurement year and ends on June 30th of the measurement year.

### Eligible Population

- Members who had a BMD Test conducted during the 730 days (24 months) prior to the fracture.
- Members who had a claim/encounter for osteoporosis therapy during the 365 days (12 months) prior to the episode date.
- Members who were dispensed an osteoporosis medication during the 365 days (12 months) prior to the fracture.

### Required Exclusions

- Members in hospice or using hospice services.
- Members who received palliative care.
- Members 67 years of age and older as of December 31st of the measurement year. Do not include laboratory claims with POS code 81.
- Members 67-80 years of age as of December 31st of the measurement year with frailty and advanced illness.

### Member Compliance

- Test the patient for osteoporosis via a BMD test within 180 days of the fracture date.
- Treat the patient with an osteoporosis medication within 180 days of the fracture date.
- Ensure member did not have osteoporosis therapy 12 months prior to the episode date.
- Members in hospice or using hospice services.
- Members who received palliative care.

### Call to Action

- Schedule fracture patients for a BMD test or prescribe an osteoporosis medication within 180 days of the fracture.
- Ensure all patients are being tested for osteoporosis yearly via a BMD test to prevent fractures and the development of osteoporosis whenever possible.
- Ensure patients fill their prescription for an osteoporosis medication at a pharmacy.

### Osteoporosis Therapies & Medications

| Drug Classification                 | Tier 1              | Tier 2              | Tier 3              | Tier 4            | Tier 5  |
|-------------------------------------|---------------------|---------------------|---------------------|-------------------|---|
| Bisphosphonates                     | Alendronate<br>(QL) | Ibandronate<br>(QL) | Risedronate<br>(QL) |                   |   |
| Selective Estrogen Receptor Blocker |                     | Raloxifene<br>(QL)  |                     |                   | Teriparatide<br>(PA; DL; QL)                                  |
| Rank Ligand Inhibitors              |                     |                     |                     | Denosumab<br>(QL) | Denosumab<br>(PA; QL)   |
| Hormones Analog                     |                     |                     |                     |                   | Abaloparatide<br>(PA; DL; QL)<br>Teriparatide<br>(PA; DL; QL) |